Drug Trial Radar · NCT05342428
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Jun 10, 2022
Primary completion
Aug 30, 2023
Study completion Aug 30, 2023
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
TLL018 tabletsDrug
Oral tablets administered at different doses BID daily for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEsTime frame: From day 1 to Weeks 12
- adverse events (AEs) according to severityTime frame: From day 1 to Weeks 12
- blood pressure from baselineTime frame: From day 1 to Weeks 12
- pulse rate from baselineTime frame: From day 1 to Weeks 12
- respiratory rate from baselineTime frame: From day 1 to Weeks 12
- temperature from baselineTime frame: From day 1 to Weeks 12
- clinical laboratory abnormalities compared to baselineTime frame: From day 1 to Weeks 12
- ECG parameters from baselineTime frame: From day 1 to Weeks 12
- physical examination findings from baselineTime frame: From day 1 to Weeks 12
- Cmax of TLL018Time frame: 0 hour (pre-dose - within 30 minutes prior to dosing), and at 0.5, 1, 2, 4 and 12 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
88 Jiefang Road, Shangcheng District, Hangzhou City, Zhejiang Province
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.